Form 4: AbbVie Executive Azita Saleki-Gerhardt Acquires Shares and Options Through Performance Awards

Azita Saleki-Gerhardt, EVP and Chief Operations Officer of AbbVie, acquired shares and options through performance-based awards and an employee stock option, increasing her beneficial ownership in the company.

Summary

• Azita Saleki-Gerhardt, an executive at AbbVie, filed a Form 4 detailing changes in her beneficial ownership of AbbVie stock.
• On February 13, 2025, she acquired 17,986 shares, 7,378 shares, 6,060 shares and 7,074 shares of AbbVie common stock under performance share and restricted stock unit awards.
• These awards were granted on February 17, 2022, February 16, 2023 and February 15, 2024, and were subject to performance-vesting restrictions based on earnings per share and relative total shareholder return or a relative return on equity measure.
• The performance-vesting restrictions were released on February 13, 2025, upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors.
• The shares will be issued to the reporting person on February 28, 2025.
• She also acquired 25,000 options to buy AbbVie common stock at an exercise price of $192.86, which become exercisable in annual increments starting February 13, 2026.
• As of January 31, 2025, she also indirectly owns 2,601 shares through an AbbVie savings program and 3,873 shares through a spousal trust.
• Following these transactions, Saleki-Gerhardt beneficially owns 232,846 directly held shares, 2,601 shares in a profit sharing trust, 3,873 shares held by her spouse in trust and 25,000 options.

Sentiment

Score: 7

Explanation: The sentiment is positive as the executive is acquiring more shares and options, and the vesting of performance-based awards indicates the company is meeting its goals. However, it's a routine filing, so the impact is moderate.

Positives

• The acquisition of shares and options by a high-ranking executive signals confidence in the company's future performance.
• The vesting of performance-based awards indicates that the company has met certain performance goals set by the board.
• The executive's increased stake in the company aligns her interests with those of shareholders.

Future Outlook

The executive will receive shares on February 28, 2025, and the options become exercisable in annual increments starting February 13, 2026.

Industry Context

Executive stock ownership is a common practice in publicly traded companies like AbbVie to align management's interests with those of shareholders. Performance-based awards are also a common incentive to drive company performance.

Comparison to Industry Standards

• AbbVie's executive compensation practices, including performance-based awards and stock options, are generally in line with industry standards for large pharmaceutical companies.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar compensation structures to incentivize their executives.
• The vesting schedules and performance metrics used by AbbVie are likely benchmarked against those of its peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• Shareholders may view the executive's increased ownership positively, as it aligns her interests with theirs.
• Employees may be motivated by the company's achievement of performance goals, which led to the vesting of these awards.

Next Steps

• The shares acquired through performance awards will be issued to the reporting person on February 28, 2025.
• The employee stock options will become exercisable in annual increments starting February 13, 2026.

Key Dates